NorthWest Biotherapeutics Inc (NWBO)

[sharpie510]

You cannot have it both ways. On the one hand, you want to interpret what Les said to mean the lower 50 performed close to 5 years, and also the upper 50 must all still be alive and living much longer than 5 years.

Out of the context of Les' interview, if someone said to me "the top 100 in trial X lived to about 5 years", I would take it at face value and interpret that to mean these 100 lived to about 5 years. Some maybe a little more, some a little less. I would also take that to mean no long tail.

We don't know the mix of the top 100. It might be there are 50 that died at 58.5 months, the 51st patient died at 58.3 months and everyone else died right after entering the trial. That would give us a mOS of 58.4 months for the top 100. Or, it might be the the lower 50 of the top 100 died right at 58.3 months, the 51st patient died at 58.5 months and the remaining 49 are still alive 58.5 months and counting. That too would produce a mOS of 58.4 months. But since this is a KM-derived mOS, it could go down, or it could improve quite a bit if there are more than 50/100 still alive and increasing that mOS. Or maybe some of the last enrolled may be making their way into the top 100 that weren't there before and are still alive (I don't know if that's possible at the point of the 2018 data).